-

IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights.

IQVIA AI Assistant is a user-friendly, conversational text interface that provides immediate and intuitive analytic insights. For the first time, customers can simply ask complex questions about their business and receive comprehensive and reliable answers in moments instead of hours or days. Available insights from IQVIA AI Assistant include brand and territory performance, competitive intelligence, prescription drivers and more.

The IQVIA AI Assistant is built upon IQVIA Healthcare-grade AI™, a trusted AI foundation that IQVIA has been investing in for more than a decade. IQVIA Healthcare-grade AI™ combines unparalleled, high-quality healthcare data with extensive privacy safeguards; fine-tuned, validated, fit-for-use models designed for use in life sciences; and quality-control benchmarking by scientific, healthcare and AI experts.

“IQVIA AI Assistant provides the precision, speed and trust required by our life sciences and healthcare customers. Through this purpose-built AI technology, we are fulfilling our mission of accelerating innovation to create a healthier world,” said Bernd Haas, senior vice president, IQVIA Digital Products and Solutions.

IQVIA is integrating its AI Assistant into a host of solutions across the portfolio, including IQVIA Orchestrated Analytics, ChannelDynamics®Verbatim, Market Prognosis and Clinical Data Analytics Solutions. For all these solutions, the addition of AI Assistant provides unique accessibility to near real-time insights that formerly required hours or days of work by subject-matter experts. Additional solutions that incorporate IQVIA AI Assistant are on the roadmap as part of a strategy to bring this new innovative capability to more customers so that they can drive healthcare forward, faster.

Learn more at https://www.iqvia.com/AIAssistant.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Contacts

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558

Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221

IQVIA

NYSE:IQV
Details
Headquarters: Durham, NC
Website: www.iqvia.com
CEO: Ari Bousbib
Employees: 90,000
Organization: OTH
Revenues: $15.4 B (2024)

Release Versions

Contacts

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558

Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221

More News From IQVIA

IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release...

IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as IQVIA’s Preferred Agentic Cloud Provider. The partnership, revealed at AWS re:Invent, is a major step in the digital transformation of healthcare and life sciences, aiming to revolutionize cli...

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today. Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Ho...
Back to Newsroom